Abstracts tagged "Anti-CCP"

Abstract Number: 1698 • ACR Convergence 2020
Polyarthritis Workup in Primary Care Setting : How Are We Doing?
Ruhani Desai¹, Cassandra Calabrese², Neel Patel³ and Jessica Donato⁴, ¹Cleveland Clinic Foundation, DeLand, FL, ²Cleveland Clinic, Cleveland, OH, ³Case Western Reserve University, Cleveland, OH, ⁴Cleveland Clinic Foundation, Cleveland
Background/Purpose: Joint pain is a common presenting complaint in Primary Care with around 54.4 million adults diagnosed with some form of arthritis per 2013 CDC survey. Polyarthritis…
Abstract Number: 2046 • ACR Convergence 2020
Alterations in Circulating CD4+ T Cell Phenotypes in CCP+ Early RA and CCP+ At-risk Individuals by Mass Cytometry
Ye Cao¹, Joshua Keegan², Alessandra Zaccardelli², Gregory Keras³, Jennifer Seifert⁴, Elizabeth Bemis⁵, Marie Feser⁶, M Kristen Demoruelle⁷, Kevin D. Deane⁸, Jill Norris⁵, Michael Brenner⁹, James Lederer¹⁰, V Michael Holers⁶, Jeffrey Sparks¹¹ and Deepak Rao², ¹Brigham and Women’s Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women’s Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁴Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Littleton, CO, ⁵Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁶Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁷University of Colorado, Denver, CO, ⁸2 Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹⁰BWH Harvard Medical School, Boston, MA, ¹¹Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: The cyclic citrullinated peptide (CCP) autoantibody is a highly specific and predictive marker for the clinical diagnosis of RA. Elevation in CCP titers can be…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].